{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122771","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.271030+00:00","generated_at":"2026-05-30T04:10:47.059695+00:00","sec_items":["1.01","1.02","2.01","2.02","2.03","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Geron posts Q3 RYTELO revenue of $28.2M; secures up to $375M in financing","bullets":["Net product revenue of $28.2M from RYTELO in first full quarter of U.S. launch.","Net loss of $26.4M ($0.04 per share) vs. $44.8M loss in Q3 2023.","Total operating expenses guidance for FY2024 set at $260M–$270M.","Received $250M gross proceeds: $125M from Royalty Pharma, $125M from Pharmakon loan.","Additional $125M debt available; $86.5M Hercules loan repaid and terminated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122771","json":"https://secwatch.observer/filing/0000950170-24-122771.json","markdown":"https://secwatch.observer/filing/0000950170-24-122771.md","text":"https://secwatch.observer/filing/0000950170-24-122771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/0000950170-24-122771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/gern-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:10:47.059695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}